Campbell & Co Investment Adviser’s Ultragenyx Pharmaceutical RARE Stock Holding History

Campbell & Co Investment Adviser’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-61,875	Closed	-$1.86M	–	1360
2025 Q3	$1.86M	Buy	61,875 +53,389	+629%	+$1.6M	0.14%	209
2025 Q2	$309K	Buy	+8,486	New	+$306K	0.02%	944
2025 Q1	–	Sell	-39,694	Closed	-$1.67M	–	1284
2024 Q4	$1.67M	Buy	+39,694	New	+$1.97M	0.13%	226
2024 Q3	–	Sell	-33,868	Closed	-$1.39M	–	1287
2024 Q2	$1.39M	Buy	+33,868	New	+$1.45M	0.12%	255
2022 Q4	–	Sell	-10,086	Closed	-$418K	–	954
2022 Q3	$418K	Buy	+10,086	New	+$518K	0.1%	369
2022 Q2	–	Sell	-7,580	Closed	-$550K	–	872
2022 Q1	$550K	Buy	7,580 +3,680	+94%	+$256K	0.15%	239
2021 Q4	$328K	Buy	3,900 +650	+20%	+$52.9K	0.11%	331
2021 Q3	$293K	Buy	3,250 +700	+27%	+$63.3K	0.1%	378
2021 Q2	$243K	Sell	2,550 -1,050	-29%	-$109K	0.1%	387
2021 Q1	$410K	Buy	+3,600	New	+$490K	0.25%	138
2019 Q4	–	Sell	-13,244	Closed	-$567K	–	818
2019 Q3	$567K	Buy	+13,244	New	+$719K	0.21%	147
2019 Q1	–	Sell	-8,790	Closed	-$423K	–	594
2018 Q4	$423K	Buy	+8,790	New	+$480K	0.42%	61

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Campbell & Co Investment Adviser's RARE Position: Q4 2025 in Review

Campbell & Co Investment Adviser sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2025, closing a stake of 61,875 shares — an estimated $1.86M sold.

Campbell & Co Investment Adviser first reported a position in RARE in Q4 2018 and held it in 12 quarters. The position peaked at $1.86M in Q3 2025. 287 funds tracked by Wall St. Rank hold RARE as of Q4 2025.

Campbell & Co Investment Adviser reported no remaining Ultragenyx Pharmaceutical position as of Q4 2025 after selling out during the quarter.
Campbell & Co Investment Adviser sold 61,875 Ultragenyx Pharmaceutical shares in Q4 2025, an estimated $1.86M.
Campbell & Co Investment Adviser first reported a position in Ultragenyx Pharmaceutical in Q4 2018 and held it in 12 quarters.
Campbell & Co Investment Adviser's Ultragenyx Pharmaceutical position peaked at $1.86M in Q3 2025.
287 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2025.

Based on Campbell & Co Investment Adviser's 13F filing for Q4 2025, filed 12 Feb 2026.